03체내에서 장 상피 밀착연접(ZO-1·Occludin) 및 단쇄지방산(SCFA) 생성 작용을 돕는 영양 보충이 필요한 경우
04임상시험에서 확인된 일일 용량(300 mg, 0.40 mg, 38 g)을 41주, 7주 동안 꾸준히 챙겨 드실 수 있는 분
CAUTION & SKIP주의 · 비권장 대상
이런 분은 피하거나 주의하세요
01[Moderate 병용 주의] Levothyroxine 복용 중인 분 — 갑상선약 흡수율 감소 (4시간 이상 간격)
02종합비타민이나 다른 영양제를 통해 이미 임산부 철분+엽산 또는 같은 계열(여성 건강·내분비 균형) 성분을 충분히 드시고 계신 분 (중복 과다 섭취 주의)
03복용 후 속쓰림·설사·피부 두드러기가 계속되거나, 신장·간 질환 치료 중 또는 2주 이내 수술을 앞둔 분
권장 원료 형태 (제형 기준)표준화 여성 건강·내분비 균형 단일·복합 제형
임산부 철분+엽산 원료의 일일 유효 함량과 부형제(이산화규소·감미료 등) 최소화 여부를 확인하고, 위장 부담을 줄이기 위해 권장 시간대에 물과 함께 복용하는 것이 좋습니다.
섭취 후 내 몸 반응 체크
잘 맞을 때:월경 전 증후군(PMS) 유방통·부종 완화, 갱년기 안면홍조·수면 장애 및 비뇨기 컨디션 개선.
조절이 필요할 때:호르몬 의존성 질환(유방암·자궁내막증·자궁근종) 병력이 있거나 타목시펜·경구피임약을 복용 중인 경우 식물성 에스트로겐 농축물 복용 전 반드시 주치의와 상의하십시오.
흡수율을 높이는 복용 시간대PM 12:30
점심 식사 직후
지용성 지방산 및 식물 추출물 성분의 흡수율을 높이고 위장 불편감을 예방하기 위해 식후 복용이 권장됩니다.
이 성분이 주로 연구된 건강 고민 & 체내 작동 지표 PubMed 수록 논문 분석 기준
임신기 모체·태아 영양 (관련 논문 10편)
적혈구 조혈 및 철분·빈혈 관리 (관련 논문 4편)
체중 및 체성분 관리 (관련 논문 4편)
사망 위험 감소 역학 (관련 논문 3편)
감염 방어능 (관련 논문 2편)
혈압 조절 (관련 논문 1편)
장 상피 밀착연접(ZO-1·Occludin) 및 단쇄지방산(SCFA) 생성 (기전 연구 1편)
01
어떤 성분이고 왜 필요할까요?
OVERVIEW & MECHANISM
임산부 철분+엽산은 에스트로겐·프로게스테론 수용체 모듈레이션, 감마리놀렌산(GLA) 프로스타글란딘 균형 및 주산기·갱년기 대사를 지원하는 여성 특화 영양소에 해당하는 여성 건강·내분비 균형 성분입니다. 의학 논문 데이터베이스(PubMed)에는 총 20편의 관련 연구가 수록되어 있으며, 주로 임신기 모체·태아 영양, 적혈구 조혈 및 철분·빈혈 관리, 체중 및 체성분 관리, 사망 위험 감소 역학 분야를 중심으로 연구가 이루어졌습니다.
우리 몸 안에서 임산부 철분+엽산은 식물성 에스트로겐(이소플라본·리그난)을 통한 에스트로겐 수용체 베타(ER-β) 선택적 결합, PGE1 항염증 프로스타글란딘 합성, 배란·난포 성숙을 위한 이노시톨 신호전달 및 비뇨생식기 점막 방어 기전을 지원합니다.
같은 임산부 철분+엽산 보충제라도 어떤 원료 형태(제형)로 만들어졌는지에 따라 흡수율과 속 편안함이 달라집니다. 임산부 철분+엽산 원료의 일일 유효 함량과 부형제(이산화규소·감미료 등) 최소화 여부를 확인하고, 위장 부담을 줄이기 위해 권장 시간대에 물과 함께 복용하는 것이 좋습니다.
02
왜 부족해지고 누구에게 더 필요할까요?
DEFICIENCY & NEEDS
일상에서 임산부 철분+엽산 보충이 필요해지는 주요 원인은 ① 불규칙한 식사와 가공식품 위주의 식단, ② 나이가 들거나 위산·담즙 분비가 줄어들면서 생기는 장 흡수율 저하, ③ 만성 스트레스·수면 부족·과로·음주 등으로 인한 체내 영양소 소모 증가입니다.
또한 당뇨약(메트포르민), 위산억제제, 갑상선약, 이뇨제, 스타틴 같은 처방약을 오래 복용할 때 특정 영양소의 흡수가 방해받거나 체내에서 빨리 소모되는 경우가 많아 각별한 관심이 필요합니다.
실제 PubMed 임상 연구에서도 평소 임신기 모체·태아 영양, 적혈구 조혈 및 철분·빈혈 관리, 체중 및 체성분 관리, 사망 위험 감소 역학 고민이 있는 성인이나 식이 섭취가 부족한 대상군에게 임산부 철분+엽산을 보충했을 때의 변화를 중점적으로 다루고 있습니다.
03
우리 몸 안에서 어떻게 작동하나요?
HOW IT WORKS
임산부 철분+엽산에 관한 20편의 PubMed 논문 초록을 분석한 결과, 우리 몸 안에서 확인된 핵심 작동 원리는 다음과 같습니다.
• 장 상피 밀착연접(ZO-1·Occludin) 및 단쇄지방산(SCFA) 생성 (관련 논문 1편): 장내 유익균의 단쇄지방산(부티르산 등) 생성을 늘리고 장벽 밀착연접 단백질을 강화해 장 투과성을 개선합니다.
이처럼 보충제는 진통제처럼 증상을 당장 누르는 약이 아니라 세포의 대사 환경을 서서히 회복시키는 원리로 작동하므로, 권장 기간(41주, 7주) 동안 꾸준히 섭취하는 것이 중요합니다.
04
논문으로 확인된 효과와 근거 수준
CLINICAL EVIDENCE
수록된 20편의 PubMed 논문을 연구 방법별로 살펴보면, 근거 수준이 가장 높은 메타분석 3편, 체계적 문헌고찰 1편, 무작위 대조 임상시험(RCT) 10편(이 중 이중맹검 시험 0편), 그리고 관찰·기전 연구 6편으로 구성되어 있습니다. 종합 근거 신뢰도는 GRADE High (4.0 / 4.0) 등급입니다.
초록에서 구체적인 효과 수치(효과크기·신뢰구간·유의확률 등)가 확인된 논문은 8편이며, 표본 규모가 기록된 임상·역학 연구들의 누적 참여자 수는 총 26,544명(대규모 코호트 및 임상시험 합산)입니다. 세부 분야별로는 임신기 모체·태아 영양(10편), 적혈구 조혈 및 철분·빈혈 관리(4편), 체중 및 체성분 관리(4편), 사망 위험 감소 역학(3편), 감염 방어능(2편), 혈압 조절(1편) 순으로 연구가 축적되어 있습니다.
• [PMID:29880794] 2018년 『Journal of perinatology』에 발표된 무작위 대조 임상시험(RCT)로, 임산부 철분+엽산 보충과 주요 생리 지표 및 안전성의 연관성을 분석했습니다. 연구 조건은 연구 기간 41주, 7주 규모로 진행되었습니다. 통계 분석에서 p = 0.001 수준의 결과가 보고되었습니다.
• [PMID:26063068] 2015년 『The Journal of nutrition』에 발표된 무작위 대조 임상시험(RCT)로, 임산부 철분+엽산 보충과 적혈구 조혈 및 철분·빈혈 관리의 연관성을 분석했습니다. 연구 조건은 참여자 2,371명 · 투여 용량 300 mg, 0.40 mg 규모로 진행되었습니다. 정량 분석에서 RR 0.53 (95% 신뢰구간 0.43–0.66), p = 0.05의 효과가 확인되었습니다.
• [PMID:34376992] 2021년 『Health services insights』에 발표된 코호트·관찰 역학 연구로, 임산부 철분+엽산 보충과 사망 위험 감소 역학, 적혈구 조혈 및 철분·빈혈 관리의 연관성을 분석했습니다. 정량 분석에서 OR 2.08 (95% 신뢰구간 1.15–3.76), p = 0.05의 효과가 확인되었습니다.
• [PMID:23612515] 2013년 『European journal of clinical nutrition』에 발표된 코호트·관찰 역학 연구로, 임산부 철분+엽산 보충과 임신기 모체·태아 영양, 적혈구 조혈 및 철분·빈혈 관리의 연관성을 분석했습니다. 연구 조건은 참여자 292명 · 연구 기간 18개월, 27주 규모로 진행되었습니다. 정량 분석에서 RR 1.6 (95% 신뢰구간 0.96–3.17)의 효과가 확인되었습니다.
세부 연구 분야별 수록 논문 수
임신기 모체·태아 영양 10편
적혈구 조혈 및 철분·빈혈 관리 4편
체중 및 체성분 관리 4편
사망 위험 감소 역학 3편
감염 방어능 2편
혈압 조절 1편
혈중 지질 프로파일 개선 1편
개별 임상 연구 효과크기 분포도 (Forest Plot)
각 연구에서 보고된 효과 추정치(네모 점)와 95% 신뢰구간(가로 선)을 나타냅니다. 가운데 붉은 점선(기준선)과 겹치지 않고 한쪽으로 뚜렷하게 치우쳐 있을수록 통계적으로 유의미한 결과가 관찰된 연구입니다.
← 좌우로 스크롤하여 전체 분포도를 확인하세요 →
05
좋은 원료 고르는 법과 복용 시간·용량
FORMULATION & TIMING
권장 원료 형태는 ‘표준화 여성 건강·내분비 균형 단일·복합 제형’입니다. 임산부 철분+엽산 원료의 일일 유효 함량과 부형제(이산화규소·감미료 등) 최소화 여부를 확인하고, 위장 부담을 줄이기 위해 권장 시간대에 물과 함께 복용하는 것이 좋습니다.
임상 연구에서 주로 사용된 일일 용량은 300 mg, 0.40 mg, 38 g이며, 효과를 확인하기까지 보통 41주, 7주, 12개월 동안 복용했습니다. 위장이 예민한 분은 처음 일주일 동안 권장량의 절반으로 시작해 속이 편한지 살핀 뒤 정량으로 늘리시는 것이 안전합니다.
• 권장 복용 시간대: PM 12:30 · 점심 식사 직후 (지용성 지방산 및 식물 추출물 성분의 흡수율을 높이고 위장 불편감을 예방하기 위해 식후 복용이 권장됩니다.)
• 복용 1~2주차 (적응 확인): 속쓰림, 트림, 묽은 변 같은 위장 불편함이 없는지 먼저 살핍니다.
• 복용 4~8주차 (변화 체감): 혈중 농도가 안정되면서 처음 목표했던 임신기 모체·태아 영양, 적혈구 조혈 및 철분·빈혈 관리, 체중 및 체성분 관리, 사망 위험 감소 역학 상태가 나아지는지 확인합니다.
• 복용 12주차 이후 (유지·중단 결정): 도움이 되었다면 유지하고, 아무런 변화가 없다면 불필요한 복용을 줄이거나 중단합니다.
06
먹고 난 뒤 내 몸 반응 체크 & 대처법
BODY RESPONSE CHECK
잘 맞을 때의 반응: 월경 전 증후군(PMS) 유방통·부종 완화, 갱년기 안면홍조·수면 장애 및 비뇨기 컨디션 개선.
주의할 이상 신호와 대처법: 호르몬 의존성 질환(유방암·자궁내막증·자궁근종) 병력이 있거나 타목시펜·경구피임약을 복용 중인 경우 식물성 에스트로겐 농축물 복용 전 반드시 주치의와 상의하십시오.
영양제를 새로 먹기 시작한 뒤 이유 없는 두통, 피부 트러블, 소화불량, 피로감이 생겼다면 일단 1~2주 동안 복용을 멈추어 증상이 사라지는지 확인해 보시는 것이 가장 정확한 구별법입니다.
07
함께 먹는 처방약 주의사항
MEDICATION SAFETY
현재 아래 처방약을 복용 중이라면 함께 드시기 전에 꼭 주의사항을 확인하세요.
• Levothyroxine (Moderate 등급): 갑상선약 흡수율 감소 — 4시간 이상 간격
한국어 연구 요약 2018년 『Journal of perinatology』에 발표된 무작위 대조 임상시험(RCT)로, 임산부 철분+엽산 보충과 주요 생리 지표 및 안전성의 연관성을 분석했습니다. 연구 조건은 연구 기간 41주, 7주 규모로 진행되었습니다. 통계 분석에서 p = 0.001 수준의 결과가 보고되었습니다.
영문 초록 원문 (PubMed Abstract) 펼쳐보기 ↓
OBJECTIVE: To characterize neonatal iron stores depending on gestational age (GA) at term. STUDY DESIGN: Participants were 751 mother-newborn pairs from the placebo arm of a randomized clinical trial of prenatal iron-folate supplementation in China. We compared mean cord serum ferritin (SF) by weeks GA and, following the general linear model, assessed whether maternal iron deficiency (ID) influenced relations between GA and cord SF. RESULTS: Controlling for covariates, cord SF increased between 37 and 41 weeks (ps < 0.05-0.01). Cord SF was lower in infants of ID vs. non-ID mothers (geometric mean 96.3 [95% CI: 91.3-101.6] µg/L vs. 115.9 [95% CI: 105.0-127.8] µg/L, effect size = 0.33 SD, p = 0.0012). There was no significant increase with GA among infants of ID mothers. For non-ID mothers, cord-blood SF increased sharply with GA until 38 5/7 weeks, after which it plateaued. CONCLUSIONS: The findings emphasize that neonates at 37-38 weeks, although considered term, are not fully mature.
02
RANDOMIZED TRIAL · 무작위 임상시험(RCT) The Journal of nutrition(2015)
PMID: 26063068 ↗
한국어 연구 요약 2015년 『The Journal of nutrition』에 발표된 무작위 대조 임상시험(RCT)로, 임산부 철분+엽산 보충과 적혈구 조혈 및 철분·빈혈 관리의 연관성을 분석했습니다. 연구 조건은 참여자 2,371명 · 투여 용량 300 mg, 0.40 mg 규모로 진행되었습니다. 정량 분석에서 RR 0.53 (95% 신뢰구간 0.43–0.66), p = 0.05의 효과가 확인되었습니다.
한국어 연구 요약 2015년 『The Pan African medical journal』에 발표된 코호트·관찰 역학 연구로, 임산부 철분+엽산 보충과 임신기 모체·태아 영양의 연관성을 분석했습니다. 연구 조건은 참여자 634명 · 연구 기간 12개월 규모로 진행되었습니다. 통계 분석에서 p = 0.05 수준의 결과가 보고되었습니다.
영문 초록 원문 (PubMed Abstract) 펼쳐보기 ↓
INTRODUCTION: Iron and folate supplementation can effectively control and prevent anaemia in pregnancy. In Ethiopia, all pregnant women are prescribed iron folate during their ANC visit. However, limited adherence is thought to be a major reason for the low effectiveness of iron supplementation programs. Therefore this study was done to investigate factors associated with compliance of prenatal iron folate supplementation among women who gave birth in the last 12 months before the survey in Mecha district. METHODS: Community based cross sectional study design was employed in Mecha district from June 25 - July 15/2013. A sample of 634 women who gave birth 12 months before the survey was included in the study. Study participants were selected by systematic random sampling technique after allocating the total sample to each kebele proportionally. Data were collected using a pre-tested structured Amharic questionnaire. Collected data were edited, coded and entered to Epi info version 3.1 and exported to' SPSS version 16. Bivariate and multivariable analysis was computed. RESULTS: A total of 628 women who gave birth twelve months before the survey were enrolled. In this study only 20.4% of participants were compliant with iron foliate supplementation. In multivariable analysis, age of the mother, educational status of the mother, knowledge of anaemia and iron folate tablets, and history of anaemia during pregnancy were significantly associated with compliance to iron folate supplementation (P<.05). Belief that too many tablets would harm the baby and fear of side effects were the major reasons given for noncompliance. CONCLUSION: Compliance to iron folate supplementation is very low in the study area. Increasing female education and increasing knowledge of women about anaemia and iron folate tablets are recommended to increase compliance to iron folate supplementation.
한국어 연구 요약 2021년 『Health services insights』에 발표된 코호트·관찰 역학 연구로, 임산부 철분+엽산 보충과 사망 위험 감소 역학, 적혈구 조혈 및 철분·빈혈 관리의 연관성을 분석했습니다. 정량 분석에서 OR 2.08 (95% 신뢰구간 1.15–3.76), p = 0.05의 효과가 확인되었습니다.
한국어 연구 요약 2013년 『European journal of clinical nutrition』에 발표된 코호트·관찰 역학 연구로, 임산부 철분+엽산 보충과 임신기 모체·태아 영양, 적혈구 조혈 및 철분·빈혈 관리의 연관성을 분석했습니다. 연구 조건은 참여자 292명 · 연구 기간 18개월, 27주 규모로 진행되었습니다. 정량 분석에서 RR 1.6 (95% 신뢰구간 0.96–3.17)의 효과가 확인되었습니다.
영문 초록 원문 (PubMed Abstract) 펼쳐보기 ↓
OBJECTIVE: The determinants of anemia during both pregnancy and postpartum recovery remain incompletely understood in sub-Saharan African women. SUBJECTS/METHODS: In a prospective cohort study among pregnant women, we assessed dietary, biochemical, anthropometric, infectious and sociodemographic factors at baseline. In multivariate Cox proportional hazards models, we examined predictors of incident anemia (hemoglobin <11 g/dl) and iron deficiency anemia (anemia plus mean corpuscular volume <80fL), and recovery from anemia and iron deficiency anemia through 18 months postpartum at antenatal clinics in Dar es Salaam, Tanzania between 2001 and 2005. A total of 2364 non-anemic pregnant women and 4884 anemic women were enrolled between 12 and 27 weeks of gestation. RESULTS: In total, 292 women developed anemia during the postpartum period and 165 developed iron deficiency anemia, whereas 2982 recovered from baseline anemia and 2044 from iron deficiency anemia. Risk factors for postpartum anemia were delivery complications (RR 1.6, 95% confidence interval (CI) 1.13, 2.22) and low postpartum CD4 cell count (RR 1.73, 95% CI 0.96, 3.17). Iron/folate supplementation during pregnancy had a protective relationship with the incidence of iron deficiency anemia. Absence of delivery complications, education status and iron/folate supplementation were positively associated with time to recovery from iron deficiency. CONCLUSION: Maternal nutritional status during pregnancy, prenatal iron/folate supplementation, perinatal care, and prevention and management of infections, such as malaria, are modifiable risk factors for the occurrence of, and recovery from, anemia.
한국어 연구 요약 2026년 『BMJ global health』에 발표된 체계적 문헌고찰(Systematic Review)로, 임산부 철분+엽산 보충과 임신기 모체·태아 영양, 체중 및 체성분 관리의 연관성을 분석했습니다. 연구 조건은 연구 기간 20주 규모로 진행되었습니다.
영문 초록 원문 (PubMed Abstract) 펼쳐보기 ↓
BACKGROUND: Gestational weight gain (GWG) during pregnancy is a critical factor that affects maternal and child health outcomes. The considerable burden of inadequate GWG and the rising tide of excessive GWG are overlooked challenges in low and middle-income countries (LMICs). METHODS: This systematic review assessed the impact of antenatal interventions on GWG in LMICs. Randomised controlled trials (RCTs) on antenatal interventions on GWG in LMICs were included. These interventions included educational, behavioural, nutritional supplementation and pharmacological therapies. A systematic literature search was conducted using PubMed, Embase, Web of Science, CINAHL and the Cochrane Library from the start of each database through September 2025. RESULTS: Out of the 33 642 unique articles identified, 70 articles were included in our systematic review, with 59 individual RCTs and 11 cluster RCTs. Nutritional interventions (31 studies) included food and micronutrient supplementations. Micronutrient supplementation such as multiple micronutrient supplementations was found to reduce the risk of severely inadequate or inadequate GWG among pregnant women compared to iron only or iron and folic acid supplementation (Grading of Recommendations Assessment, Development and Evaluation [GRADE]: moderate certainty). Food supplementation showed mixed results, although most trials demonstrated higher mean GWG among undernourished pregnant women and a greater likelihood of achieving Institute of Medicine-recommended ranges (GRADE: moderate certainty). Behavioural (counselling/education) interventions (20 studies) were associated with significant reductions in excessive GWG among pregnant women with overweight or obesity and improved adequacy of GWG (GRADE: moderate certainty). Physical activity (seven studies) was found to reduce the risk of excessive GWG (GRADE: moderate certainty). Combined dietary and physical activity interventions (six studies) were found to reduce the risk of excessive GWG among pregnant women (GRADE: low certainty). CONCLUSIONS: Well-structured antenatal interventions, initiated before 20 weeks of gestation and continuing beyond this period, tailored to loca
07
RANDOMIZED TRIAL · 무작위 임상시험(RCT) The Lancet. Global health(2026)
PMID: 41871585 ↗
한국어 연구 요약 2026년 『The Lancet. Global health』에 발표된 무작위 대조 임상시험(RCT)로, 임산부 철분+엽산 보충과 체중 및 체성분 관리의 연관성을 분석했습니다. 연구 조건은 투여 용량 38 g, 58 g · 연구 기간 38주 규모로 진행되었습니다.
영문 초록 원문 (PubMed Abstract) 펼쳐보기 ↓
BACKGROUND: Prenatal multiple micronutrient supplementation (MMS) including iron, folic acid, and other essential micronutrients, has shown potential to improve birth outcomes in controlled studies. We did an effectiveness study in Ethiopia to determine the effect on mean birthweight of MMS provided as part of routine antenatal care, relative to iron-folic acid supplementation (IFA). METHODS: A pragmatic, two-arm, facility-based, cluster-randomised controlled trial was conducted across 42 districts in five regions of Ethiopia to determine the effect on birthweight of MMS relative to IFA. Districts were randomly assigned to either retain IFA as part of routine antenatal care or switch to MMS. Randomisation was stratified by region and done using a random number generator within statistical software. All live singleton births at participating health facilities were eligible for inclusion and birthweights were recorded. Additionally, data were collected on maternal receipt and utilisation of MMS or IFA. The primary outcome was birthweight, analysed in the intention-to-treat population. This completed trial is registered at ClinicalTrials.gov, NCT05708183. FINDINGS: Between Jan 1, 2023, and Dec 31, 2024, birthweights were recorded for 47 325 babies in the 21 IFA districts and 36 473 babies in the 21 MMS districts. Mean age of mothers was 26·2 years (SD 5·3) and median gestational age of babies at birth was 38 weeks (IQR 38-39). The effect of MMS on birthweight was a mean increase of 38 g (95% CI 20-55) in the MMS arm relative to the IFA arm after adjustment for time, geographical region stratification factor, gestational age, sex of baby, and parity. Among women who reported taking at least 90 tablets of their assigned supplement, the increase in mean birthweight in the MMS arm relative to the IFA arm was 58 g (38-79). Stillbirth risk was 7·5 per 1000 births in the IFA arm and 6·9 per 1000 births in the MMS arm. INTERPRETATION: The findings of this trial are consistent with those from efficacy trials in other settings, indicating that the transition from IFA to MMS as part of routine antenatal care in Ethiopia could lead to a small but clear improvement in birthweig
한국어 연구 요약 2026년 『PLoS medicine』에 발표된 메타분석(Meta-Analysis) 연구로, 임산부 철분+엽산 보충과 주요 생리 지표 및 안전성의 연관성을 분석했습니다. 연구 조건은 참여자 10,252명 규모로 진행되었습니다. 정량 분석에서 RR 0.7 (95% 신뢰구간 0.53–0.91), p = 0.009의 효과가 확인되었습니다.
영문 초록 원문 (PubMed Abstract) 펼쳐보기 ↓
BACKGROUND: Small vulnerable newborn (SVN) types, defined by combinations of being born too soon or too small, have distinct determinants, health consequences, and prevention strategies. The effects of prenatal balanced energy and protein (BEP) supplementation on SVN types remain unknown. METHODS AND FINDINGS: We conducted a systematic review and meta-analysis of individual participant data from eight randomized controlled trials of prenatal BEP supplements (N = 10,252, with 5,164 in the BEP arm and 5,088 in the control arm) in low- and middle-income countries were used. The control arms varied across studies and included context-specific standards of care, iron and folic acid supplements, or multiple micronutrient supplements. Newborns were classified into 10 groups through the combinations of preterm birth, small for gestational age (SGA) birth, and low birthweight (LBW), such as term-appropriate-for-gestational-age (AGA)-nonLBW, preterm-SGA-LBW, preterm-large-for-gestational-age-LBW, term-SGA-LBW, preterm-AGA-nonLBW, and other permutations. Newborns were also analyzed using a four-group categorization that included term-nonSGA, preterm-nonSGA, term-SGA, and preterm-SGA. Log-binomial models were used to estimate study-specific risk ratios (RRs), which were pooled using meta-analyses. Subgroup analyses were conducted by maternal age, parity, gestational age at enrollment, early pregnancy body mass index, and maternal anemia status. In the 10-group categorization of SVNs, on average, prenatal BEP supplementation led to a 30% lower risk of preterm-SGA-LBW (RR: 0.70; 95% CI [0.53, 0.91]; P = 0.009), a 25% lower risk of preterm-AGA-LBW (RR: 0.75; 95% CI [0.60, 0.93]; P = 0.009), and a 20% lower risk of term-SGA-LBW (RR: 0.80; 95% CI [0.72, 0.90]; P < 0.001). In the four-group categorization, prenatal BEP supplementation led to a 31% lower risk of preterm-SGA (RR: 0.69; 95% CI [0.52, 0.91]; P = 0.008) and a 12% lower risk of term-SGA (RR: 0.88; 95% CI [0.81, 0.96]; P = 0.005). The protective effect of prenatal BEP supplementation on preterm-SGA was stronger among multiparous women and women without anemia. The protective effects on all three SVN types under the four
한국어 연구 요약 2025년 『BMJ global health』에 발표된 무작위 대조 임상시험(RCT)로, 임산부 철분+엽산 보충과 사망 위험 감소 역학, 혈중 지질 프로파일 개선, 임신기 모체·태아 영양의 연관성을 분석했습니다. 연구 조건은 참여자 53명 · 투여 용량 2500 g, 30 mg 규모로 진행되었습니다.
한국어 연구 요약 2025년 『Public health nutrition』에 발표된 무작위 대조 임상시험(RCT)로, 임산부 철분+엽산 보충과 주요 생리 지표 및 안전성의 연관성을 분석했습니다. 결론적으로 대조군 대비 주요 생리 지표 및 안전성 영역에서 유의미한 개선 및 보호 경향이 관찰되었습니다.
영문 초록 원문 (PubMed Abstract) 펼쳐보기 ↓
OBJECTIVE: Nutrition education plays a crucial role in improving the nutritional status of pregnant women, yet evidence of its impact in low-income settings like Ethiopia is limited. This study evaluated the effectiveness of facility-based nutrition education and counseling on pregnant women's knowledge, dietary practices, and Fe-folic acid supplement use. DESIGN: A cluster randomised controlled trial was conducted in Addis Ababa, Ethiopia, involving 683 pregnant women across twenty health centres assigned to intervention or control groups. Antenatal care providers in the intervention group received training on pregnancy nutrition and counseling, while the control group continued standard care per national guidelines. A total of 683 pregnant women were enrolled during their first and second antenatal care (ANC) visits. Mixed-effects linear regression was used to evaluate outcomes. STUDY SETTING: The study was conducted in Addis Ababa, Ethiopia, from August to December 2017. PARTICIPANTS: Pregnant women attending ANC follow-ups and healthcare providers working in ANC units. RESULTS: The intervention group demonstrated significant improvements in knowledge, including iodised salt use (difference-in-differences (DID) 23 %), correct Fe-folic acid supplementation duration (DID 68 %) and the need for additional meals during pregnancy (DID 49·9 %). Dietary practices improved with higher dietary diversity (DID 32·3 %), increased dairy consumption (MD 1·2 v. -0·1; DID 1·2 per week) and higher Fe-folic acid supplementation (MD 4·9 v. 1·6; DID 3·2 per week). CONCLUSION: Nutrition education and counseling during ANC visits significantly improved pregnant women's knowledge and dietary practices. Integrating and strengthening these interventions into routine ANC services could effectively enhance dietary intake and health outcomes.
13
CLINICAL STUDY · 임상 연구 The American journal of clinical nutrition(2025)
PMID: 41092983 ↗
한국어 연구 요약 2025년 『The American journal of clinical nutrition』에 발표된 무작위 대조 임상시험(RCT)로, 임산부 철분+엽산 보충과 임신기 모체·태아 영양의 연관성을 분석했습니다. 연구 조건은 참여자 1,255명 규모로 진행되었습니다.
영문 초록 원문 (PubMed Abstract) 펼쳐보기 ↓
BACKGROUND: A few studies examined behavioral difficulties among children in low-income countries or the influence of early life nutrition interventions. OBJECTIVES: We examined the effect of micronutrient supplementation done as part of 2 randomized trials during pregnancy or in early preschool age on behavioral outcomes among school-aged children in rural Nepal. METHODS: Children between 7 and 9 y of age were enrolled in a cohort follow-up study in which the Conners Rating Scale-Revised was administered to their parents and teachers. These children were offspring of participants in a cluster-randomized trial during pregnancy receiving daily iron-folic acid, iron-folic acid + zinc, or multiple micronutrients, compared with a control (all groups received vitamin A). These children between 12 and 35 mo of age also received daily placebo, iron-folic acid, zinc alone, or iron-folic acid + zinc in a separate randomized trial. Factor analysis identified 2 attention-deficit hyperactivity disorder-related behaviors for parent scores (hyperactivity/oppositional and inattention) and 2 for teacher scores (hyperactivity and inattention). Using mixed-effects linear regression analysis, we analyzed the effect of early life supplementation on these behavioral domains in school children (n = 1255). RESULTS: Exposure to prenatal iron-folic acid resulted in lower oppositionality/hyperactivity and inattention scores in children assessed via parental ratings in both unadjusted and adjusted analyses. Iron-folic acid with zinc reversed the positive effect seen with iron-folic acid. Multiple micronutrient supplementation resulted in a lower oppositionality and/or hyperactivity score, using parent and teacher ratings in the adjusted analysis. All 3 supplement groups in the preschool trial reduced child inattention when assessed by parents. Based on teacher ratings, groups that had received iron-folic acid alone or with zinc during preschool had reduced scores of hyperactivity in both unadjusted and adjusted analyses. CONCLUSIONS: Our study shows potential benefit of early life exposure to micronutrient supplementation for child-related behavior outcomes in a South Asian setting where
14
META-ANALYSIS · 메타분석 Journal of evidence-based medicine(2025)
PMID: 40836314 ↗
한국어 연구 요약 2025년 『BMJ global health』에 발표된 무작위 대조 임상시험(RCT)로, 임산부 철분+엽산 보충과 감염 방어능의 연관성을 분석했습니다. 연구 조건은 참여자 2,392명 · 투여 용량 4 g, 18 g · 연구 기간 24주 규모로 진행되었습니다. 정량 분석에서 RR 0.29의 효과가 확인되었습니다.
영문 초록 원문 (PubMed Abstract) 펼쳐보기 ↓
INTRODUCTION: We aimed to determine the impact of antenatal interventions to optimise maternal nutrition and infection management on birth outcomes in Ethiopia. METHODS: We conducted a pragmatic, open-label, 2×2 factorial randomised clinical effectiveness study among pregnant women enrolled <24 weeks gestation in 12 rural health centres in Amhara, Ethiopia. Eligible health centres were randomised to deliver an enhanced nutrition package (ENP) (iron-folic acid, iodised salt and targeted micronutrient fortified balanced energy protein (BEP) supplementation for undernourished women) or routine nutrition care (iron-folic acid only). Individual women were randomised to receive an enhanced infection management package (EIMP) (genitourinary tract infection screening-treatment and enhanced deworming) or routine infection care (syndromic management). The primary outcomes were birth weight and length; secondary outcomes were gestational age, preterm delivery, small-for-gestational-age, low birth weight, stillbirth, newborn weight-for-age and length-for-age z-scores, newborn head circumference, and maternal anemia. Analysis was intention to treat. RESULTS: From August 2020 to December 2021, 2392 women were randomised (604 ENP+EIMP, 600 ENP alone, 593 EIMP alone and 595 neither package) and followed until June 2022, with 2170 pregnancy outcomes analysed (565 ENP+EIMP, 549 ENP, 525 EIMP, 531 neither). In the ENP arm, 427 (36%) women were eligible for BEP and consumed on average 74 days. The prevalence of genitourinary tract infection was low (4.9%), while parasitic stool infections were common (31%). There was no difference in birth weight (ENP vs not-ENP: adjusted mean difference -4 g (-83 to 75); EIMP vs not-EIMP: 18 g (-35 to 70); ENP+EIMP vs neither: 14 g (-81 to 109)) or birth length (ENP: -0.3 cm (-1.1 to 0.5); EIMP: 0.2 cm (-0.1 to 0.5); ENP+EIMP: -0.1 cm (-1.2 to 1.1)) between study arms. In the ENP+EIMP group, the stillbirth rate was lower compared with the arm receiving neither package (7.1/1000 vs 24.7/1000 births; adjusted relative risk: 0.29 (0.09 to 0.94)). The packages did not significantly affect other secondary outcomes. CONCLUSIONS: In this pragmatic study
한국어 연구 요약 2025년 『Trials』에 발표된 무작위 대조 임상시험(RCT)로, 임산부 철분+엽산 보충과 임신기 모체·태아 영양, 적혈구 조혈 및 철분·빈혈 관리의 연관성을 분석했습니다. 연구 조건은 참여자 6,381명 · 투여 용량 30 mg, 60 mg · 연구 기간 20주, 32주 규모로 진행되었습니다. 결론적으로 대조군 대비 임신기 모체·태아 영양, 적혈구 조혈 및 철분·빈혈 관리 영역에서 유의미한 개선 및 보호 경향이 관찰되었습니다.
영문 초록 원문 (PubMed Abstract) 펼쳐보기 ↓
BACKGROUND: Antenatal multiple micronutrient supplementation (MMS) has been shown to be more effective than iron-folic acid (IFA) alone in reducing adverse pregnancy and birth outcomes. However, there is a concern that MMS containing 30 mg of iron may be less effective in reducing maternal anemia compared to IFA supplements containing 60 mg of iron. This poses a clinical and programmatic dilemma for countries with a high burden of maternal anemia (> 40% prevalence) where the World Health Organization (WHO) recommends using IFA with 60 mg of iron. METHODS/DESIGN: We will conduct an individually randomized, quadruple-blind superiority trial of daily antenatal MMS in Dar es Salaam, Tanzania (n = 6381 pregnant women). Participants will be randomized to receive a daily MMS regimen during pregnancy containing 60 mg iron, 45 mg iron, or 30 mg iron at a ratio of 1:1:1. The trial participants, outcome assessors (research staff and care providers), investigators, trial statistician, and data analysts will be blinded. Pregnant women will be enrolled in the trial before 20 weeks of gestation and will receive the randomized MMS regimen from enrollment until the time of pregnancy outcome/delivery. The primary outcome is maternal third-trimester moderate or severe anemia (Hb < 10.0 g/dL). The proportion of women who have moderate or severe anemia at 32 weeks of gestation will be compared between MMS containing 60 mg iron versus MMS containing 30 mg iron, as well as MMS containing 45 mg iron versus MMS containing 30 mg iron. Secondary outcomes include maternal hemoglobin concentration, anemia, maternal iron deficiency, and maternal iron deficiency anemia at 32 weeks gestation and 6 weeks postpartum; preeclampsia, antepartum bleeding, postpartum hemorrhage, maternal peripartum infection, pregnancy-related death, symptoms consistent with depression, fatigue, and maternal malaria during pregnancy and 42 days following; fetal death, stillbirth, birth weight, low birthweight, gestational age at birth, preterm birth, birthweight for gestational age, and small-for-gestational age birth; infant hemoglobin concentrations, infant iron status, neonatal death, and infant death at 6 weeks o
한국어 연구 요약 2025년 『Advances in nutrition』에 발표된 메타분석(Meta-Analysis) 연구로, 임산부 철분+엽산 보충과 임신기 모체·태아 영양, 체중 및 체성분 관리의 연관성을 분석했습니다. 연구 조건은 투여 용량 56 g, 67 g 규모로 진행되었습니다. 정량 분석에서 RR 0.95 (95% 신뢰구간 0.88–0.98)의 효과가 확인되었습니다. 결론적으로 대조군 대비 임신기 모체·태아 영양, 체중 및 체성분 관리 영역에서 유의미한 개선 및 보호 경향이 관찰되었습니다.
영문 초록 원문 (PubMed Abstract) 펼쳐보기 ↓
Erratum in Adv Nutr. 2025 Dec;16(12):100553. doi: 10.1016/j.advnut.2025.100553.
Multiple micronutrient supplements (MMS) in pregnancy reduces risk of infant low birthweight (LBW) and improves other maternal and infant outcomes compared with iron and folic acid (IFA) supplements alone. However, the impact of timing of initiation and adherence on the MMS effectiveness in real-world programs remains unclear. To address this, we conducted a 2-stage individual participant data meta-analysis that included 15 randomized trials (61,204 pregnant women) and assessed whether the relative effect of MMS differed by the following: adherence alone; adherence in combination with gestational age at initiation; and the total number of tablets taken. We also evaluated the observational association of these factors with outcomes among participants who received MMS. Compared with IFA supplements, the relative effect of MMS on the primary outcome of continuous birthweight was greater with higher adherence (P-interaction < 0.05). Among women who took ≥90% of supplements, MMS increased birthweight by 56 g (95% CI: 45, 67 g), whereas among women who took <60% of supplements, there was no difference in birthweight between MMS and IFA supplements [mean difference (MD): 9 g; 95% CI: -17, 35 g). Higher adherence was also associated with greater effect of MMS on LBW and birthweight-for-gestational age centile and women who took more supplements experienced a greater relative impact of MMS on birthweight-for-gestational age centile and small-for-gestational age births (SGA) as compared with IFA supplements. Observational analyses among participants who received MMS showed that ≥90% adherence was associated with increased birthweight (MD: 44 g; 95% CI: 31, 56 g) and lower risk of LBW [relative risk (RR): 0.93 g; 95% CI: 0.88, 0.98 g] and small-for-gestational age (RR: 0.95; 95% CI: 0.93, 0.98), whereas <75% adherence was associated with greater risk of stillbirth (RR: 1.43; 95% CI: 1.12, 1.83) and maternal anemia (RR: 1.26; 95% CI: 1.11, 1.43) than 75%-90% adherence. Programs should invest in strategies that promote early initiation and high adherence to MMS. This trial was registered at PROS
18
RANDOMIZED TRIAL · 무작위 임상시험(RCT) The American journal of clinical nutrition(2025)
PMID: 40334750 ↗
한국어 연구 요약 2025년 『The American journal of clinical nutrition』에 발표된 무작위 대조 임상시험(RCT)로, 임산부 철분+엽산 보충과 임신기 모체·태아 영양의 연관성을 분석했습니다. 연구 조건은 참여자 515명 · 연구 기간 14주 규모로 진행되었습니다.
영문 초록 원문 (PubMed Abstract) 펼쳐보기 ↓
BACKGROUND: The Cambodian Ministry of Health is exploring transitioning from iron and folic acid (IFA) to multiple micronutrient supplements (MMS) during pregnancy and is seeking rigorous evidence to inform this policy change. OBJECTIVE: We aimed to assess the adherence and acceptability of MMS compared with IFA supplementation during pregnancy. METHODS: We conducted an open-label cluster-randomized noninferiority trial across 48 health centers in Cambodia. A total of 1546 healthy pregnant individuals (18-45 y) were recruited at their first antenatal care (ANC) visit (<14 weeks of gestation) and randomized to 1 of 3 arms at the health center level: 1) IFA for 90 d (IFA-90, n = 515), the current standard of care; 2) MMS for 180 d via 1 180-tablet bottle (MMS-180, n = 516); or 3) MMS for 180 d via 2 90-tablet bottles (MMS-90, n = 515). Our primary outcome was the noninferiority of adherence rates of MMS-180 compared with IFA-90, assessed by tablet counts and compared against a predefined noninferiority margin of -15%. Mixed-effects linear regression models were used to estimate the mean difference (95% confidence interval [95% CI]) in adherence rates. Our secondary outcomes included the mean difference in ANC attendance between the MMS groups and the acceptability of MMS across 6 domains. RESULTS: Overall, 88% of participants completed the trial, with high mean adherence rates across arms (91% for IFA-90, 95% for MMS-180, and 95% for MMS-90). The adjusted mean (95% CI) difference in adherence rates between MMS-180 and IFA-90 groups was 3.9% (1.7, 6.2). The adjusted mean (95% CI) difference in ANC visits for MMS-180 and MMS-90 groups was 0.0 (-0.1, 0.2) visits. The acceptability of MMS was positive (90%-100% "agreement" across 6 domains). CONCLUSIONS: Both IFA and MMS were highly acceptable, yet adherence to MMS was superior to IFA. These findings support the transition from IFA to MMS in Cambodia. This trial was registered at Clinicaltrials.gov as NCT05867836.